FDA’s draft guidance on common issues for rare disease drug development appears to be a type of primer for patient groups and sponsors new to the sector.
As Orphan Drugs Gain More Attention, FDA Releases Development Guidance
Straightforward draft document seems aimed at entities that have limited experience working with the agency.